Darapladib
 | |
| Clinical data | |
|---|---|
| Other names | SB-480848 |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
Darapladib is an inhibitor of
drug for treatment of atherosclerosis.[1]
It was discovered by
GlaxoSmithKline (GSK).[2]
In November 2013, GSK announced that the drug had failed to meet Phase III endpoints in a trial of 16,000 patients with acute coronary syndrome (ACS).[3] An additional trial of 13,000 patients (SOLID-TIMI 52) finished in May 2014. The study failed to reduce the risk of coronary heart disease death, myocardial infarction, and urgent coronary revascularization compared with placebo in acute coronary syndrome patients treated with standard medical care.[4]
In 2022, Darapladib has been found to inhibit
intraerythrocytic development of the malaria parasite Plasmodium falciparum by inhibition of the human host enzyme peroxiredoxin 6.[5] The authors present data that the original target of Darapladib, Lp-PLA2, is absent in the host red blood cell
.
References
- PMID 23973042.
- ^ "Spotlight on Glaxo Heart Drug as Others Fail". CNBC. Reuters. 12 April 2007.
- ^ Carroll J (12 November 2013). "GlaxoSmithKline loses its first big PhIII bet on heart drug darapladib". Fierce Biotech.
- ^ "GSK announces phase III study with darapladib did not meet primary endpoint in patients following an acute coronary syndrome". GlaxoSmithKline plc. 13 May 2014. Archived from the original on 14 July 2014. Retrieved 2 July 2014.
- PMID 35705035.